Literature DB >> 3416004

Incorporation of mevalonate into dolichol and other isoprenoids during estrogen-induced chick oviduct differentiation.

S C Seifert1, J J Lucas.   

Abstract

Incorporation of [14C]mevalonate into dolichol and other isoprenoid compounds by chick oviduct explants has been studied. A reliable assay of dolichol biosynthesis employing several chromatographic procedures, including two-dimentional TLC, was developed. Incorporation of [14C]mevalonate into dolichol by oviduct explants was linear for at least 6 h. The effect of estrogen-induced differentiation was studied by incubation of explants obtained from chicks treated for various periods of time with diethylstilbestrol. Mevalonate incorporation into dolichol, when expressed as cpm per g of tissue, was not affected by estrogen treatment, but since the oviduct increased about 100-fold in mass during differentiation, each oviduct synthesizes about 100-fold more dolichol. In most tissues, the major product of mevalonate incorporation is cholesterol. However, although approx. 90% of the non-saponifiable 14C-labeled compounds were in the so-called 'cholesterol fraction', oviduct explants from estrogenized chicks synthesized little, if any, cholesterol. A number of cholesterol biosynthetic intermediates were observed, with compounds comigrating with squalene and lanosterol accounting for about 50% of the total. Since the estrogenized chick has serum cholesterol levels in the range of 800-900 mg/dl, these results suggest that oviduct has secondary control points which allow it to inhibit cholesterol synthesis when mevalonate is used as the precursor. In support of this hypothesis is the observation that explants from untreated chicks can incorporate mevalonate into cholesterol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3416004     DOI: 10.1016/0005-2760(88)90090-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis.

Authors:  I Campia; C Lussiana; G Pescarmona; D Ghigo; A Bosia; C Riganti
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

2.  Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.

Authors:  Marta Coscia; Elena Quaglino; Manuela Iezzi; Claudia Curcio; Francesca Pantaleoni; Chiara Riganti; Ingunn Holen; Hannu Mönkkönen; Mario Boccadoro; Guido Forni; Piero Musiani; Amalia Bosia; Federica Cavallo; Massimo Massaia
Journal:  J Cell Mol Med       Date:  2010-12       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.